EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 167 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Cancer Control in American Indian and Alaska Native Populations: A Conversation... April 25, 2018 The Timing for the Age of which Natural Menopause Occurs August 3, 2023 Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... July 1, 2020 Opinion: ‘We can’t afford to stop now’ November 30, 2020 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec On Giving Tuesday, You Helped Us Raise $334,449 For People, Pets,... New Risk Model Aims to Reduce Breast Cancer Disparities in Black... Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers
